3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2/3
2
Phase 2
2
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Adenoviridae Infections
1
Interventions
Gemcitabine
9
Docetaxel
8
Androgen Antagonists
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
6
Magnetic Resonance Spectroscopy
6
gallium 68 PSMA-11
5
Prednisone
5
Leuprolide
5
Goserelin
5
Cisplatin
5
enzalutamide
4
bicalutamide
4
Triptorelin Pamoate
4
Radiosurgery
4
Carboplatin
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
luprolide acetate gel depot
3
Flutamide
3
Celecoxib
3
valrubicin
2
pembrolizumab
2
nilutamide
2
cabazitaxel
2
abiraterone
2
Zoledronic Acid
2
Vinblastine
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
valrubicin
×
Genitourinary
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled
NCT01316874
2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3
Completed
90 enrolled